Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 20, 2006. The report serves as a notification of transactions involving directors, specifically detailing changes in interests in American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
No material financial changes versus prior periods are reported. The only disclosed change is the provisional allocation of 127.25 ADSs to Non-Executive Director Dr. Daniel Podolsky on October 19, 2006. This allocation relates to his service as the Board's nominated Scientific/Medical Expert for the period of July 1, 2006, to September 30, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to compliance with Disclosure Rule 3.1.4R(1)(b) regarding director transactions.
Investor Verification Points
- Verify the total number of ADSs held by Dr. Daniel Podolsky following this allocation.
- Confirm the terms of the share allocation arrangements for Non-Executive Directors for the specified service period.
- Review the company's Form 20-F for comprehensive financial results, as this 6-K does not include them.